Latest Breaking News On - Alpha bronze - Page 9 : vimarsana.com

NLS Pharmaceutics AG: NLS Pharmaceutics Ltd Announces US$4 4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ZURICH, SWITZERLAND / ACCESSWIRE / April 13, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery

United statesNew yorkAlex zwyerRonald hafnerKostenloser wertpapierhandelCindy rizzoPascal nigenExchange commissionAlpha bronzeA gp alliance global partnersEarly access programPharmaceutics ltdAlliance global partnersSecurities actCommon warrantsMazindol controlled release

NLS Pharmaceutics Ltd Announces US$4 4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

NLS Pharmaceutics Ltd Announces US$4 4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkAlex zwyerRonald hafnerCindy rizzoPascal nigenExchange commissionAlpha bronzeA gp alliance global partnersEarly access programPharmaceutics ltdAlliance global partnersSecurities actCommon warrantsMazindol controlled releaseOrphan drug designations

NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements

NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.

United statesAlex zwyerCindy rizzoPascal nigenAlpha bronzeEarly access programPharmaceutics ltdListing qualificationsNasdaq stock marketNasdaq capitalNasdaq listing ruleNasdaq marketplace ruleMazindol controlled releaseOrphan drug designationsUnited states wire group

NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements

NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.

NLS Pharmaceutics AG: NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements

ZURICH, SWITZERLAND / ACCESSWIRE / April1, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery

United statesAlex zwyerKostenloser wertpapierhandelCindy rizzoPascal nigenAlpha bronzeEarly access programPharmaceutics ltdListing qualificationsNasdaq stock marketNasdaq capitalNasdaq listing ruleNasdaq marketplace ruleMazindol controlled releaseOrphan drug designations